81 -11 (49) 2022 — AkbarovaD.S.,KomolovaF.Dj. — THE ROLE OF PHARMACOECONOMIC ANALYSIS IN THE MODERN HEALTH CARE SYSTEM

THE ROLE OF PHARMACOECONOMIC ANALYSIS IN THE MODERN HEALTH CARE SYSTEM

AkbarovaD.S., Tashkent Medical Academy, Uzbekistan

KomolovaF.Dj., Tashkent Medical Academy, Uzbekistan

YakubovA.V., Tashkent Medical Academy, Uzbekistan

ZufarovP.S., Tashkent Medical Academy, Uzbekistan

MusayevaL.J., Tashkent Medical Academy, Uzbekistan

AbdusamatovaD.Z. Tashkent Medical Academy, Uzbekistan

Resume

The main task of pharmacoeconomics in the modern healthcare system is the choice of the rational use of financial resources to obtain the maximum possible socio-economic effect in the future. In the context of limited budgetary funds, growing costs of the health care system in general and drug provision in particular, pharmacoeconomics is a scientifically based choice of one or another treatment method, makes it possible to compose of formularies of medicines, free and reduced lists of medicines. In other words, pharmacoeconomics provides the state and practical healthcare system with mechanisms for the effective use of budgetary funds allocated for drug provision.

Keywords: pharmacoeconomics, medicines, economic efficiency, medical insurance.

First page

459

Last page

465

For citation:AkbarovaD.S., KomolovaF.Dj., YakubovA.V., ZufarovP.S., MusayevaL.J., AbdusamatovaD.Z. THE ROLE OF PHARMACOECONOMIC ANALYSIS IN THE MODERN HEALTH CARE SYSTEM //New Day in Medicine 11(49)2022 459-465 https://clck.ru/32se4A

LIST OF REFERENCES:

  1. Андрианова Г. Н., Каримова А. А., Бадаев Ф.И. Фармакоэкономика. Екатеринбург 2017 196 с.
  2. Воробьев П.А. Клинико-экономический анализ /М. «Ньюдиамед», 2008, 778 с.
  3. Madiyeva R.  Davlat tibbiy sug’urta tizimi: maqsad, vazifa va kafolat. /“Yangi O’zbekiston” 23.12.2020.
  4. Brandão SMG, Rezende PC, Brunner-La Rocca H-P, et al. Comparative costeffectiveness of surgery, angioplasty, or medical therapy in patients with multivessel  coronary artery disease: MASS II trial.Cost Eff Resour Alloc. 2018;16(1):55
  5. Bastida J.L., Aguilar P.S., González B.D. The economic costs of traffic accidents in Spain. //J Trauma. 2014;56(4):883–889
  6. Drummond M.F., Sculpher M.J., Claxton K., Stoddart G.L., Torrance GW. Methods for the Economic Evaluation Of Health Care Programmes. Oxford: Oxford University Press; 2015.
  7. Emamgholipour S., Sari A.A., Pakdaman M., Geravandi S. Economic burden of cardiovascular disease in the southwest of Iran. //Int Cardiovas Res J. 2018;12(1)
  8. Gholami S.S., Azar Fe.F., Rezapour A., Tajdini M. Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review. //Heart Fail Rev. 2019:1–9.
  9. John D., Chatterjee P., Murthy S., et al. Cost effectiveness of decentralised care model for managing MDR-TB in India. Indian J Tuberc. 2018; 65 (3): 208–17
  10. Lopez-Bastida J., Boronat M., Moreno J.O., Schurer W. Costs, outcomes and challenges for diabetes care in Spain. Global Health. 2013; 9(1):17. WHO Collaborating Centre for Drug Statistics Methodology.
  11. Marks S.M., Mase S.R., Morris S.B. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017; 64 (12): 1670–7
  12. Masuku S.D., Berhanu R., Van Rensburg C., et al. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. //Int J Tuberc Lung Dis. 2020; 24 (4): 376–82
  13. Nsengiyumva N.P., Mappin-Kasirer B., Oxlade O., et al. Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support. //Eur Respir J. 201
  14. Van Rensburg C., Berhanu R., Hirasen K., et al. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. PLoS One. 2019
  15. Vieira RDO, Hueb W., Hlatky M. et al. Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial. //Circulation. 2012;126(11 suppl 1):S145–S150
  16. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2022.

file

download